![](https://porib.com/wp-content/uploads/2021/07/clinicoeconomics_and_outcomes_research.jpg)
Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, Soto J
Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
ClinicoEconomics and Outcomes Research. 2023:15 659–671
![](https://porib.com/wp-content/uploads/2021/07/clinicoeconomics_and_outcomes_research.jpg)
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyagüez I, Brockbank J, Iglesias T, Llinares J, Sierra J
Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with CD-33 positive acute myeloid leukaemia in Spain
ClinicoEconomics and Outcomes Research 2021; 13:263-277
![](https://porib.com/wp-content/uploads/2021/07/clinicoeconomics_and_outcomes_research.jpg)
Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G